S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
NASDAQ:AXSM

Axsome Therapeutics - AXSM Stock Forecast, Price & News

$68.70
-5.59 (-7.52%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$67.91
$73.83
50-Day Range
$62.16
$79.72
52-Week Range
$20.63
$82.00
Volume
1.91 million shs
Average Volume
916,556 shs
Market Capitalization
$2.98 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$108.15

Axsome Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
57.4% Upside
$108.15 Price Target
Short Interest
Bearish
22.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.45mentions of Axsome Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.43) to ($3.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

105th out of 1,025 stocks

Pharmaceutical Preparations Industry

44th out of 498 stocks

AXSM stock logo

About Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
AXSM April 21st Options Begin Trading
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
2 Promising New Growth Stocks to Watch in 2023
AXSM Axsome Therapeutics, Inc.
2 Stocks That Could Double Your Money in 2023
Got $5,000? 2 Unstoppable Stocks to Buy and Hold
TG Therapeutics: Would Santa Deliver An Early Present?
Axsome Therapeutics Stock: Bear vs. Bull
See More Headlines
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Company Calendar

Last Earnings
11/07/2022
Today
2/05/2023
Next Earnings (Confirmed)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXSM
Employees
108
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$108.15
High Stock Price Forecast
$210.00
Low Stock Price Forecast
$75.00
Forecasted Upside/Downside
+57.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-130,400,000.00
Pretax Margin
-622.89%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.41 per share

Miscellaneous

Free Float
32,135,000
Market Cap
$2.98 billion
Optionable
Optionable
Beta
1.95

Key Executives

  • Herriott Tabuteau
    Chairman & Chief Executive Officer
  • Mark L. Jacobson
    Chief Operating Officer
  • Nick PizzieNick Pizzie
    Chief Financial Officer
  • Joseph Debrah-Afful
    Controller
  • Amanda Jones
    Senior Vice President-Clinical Development













AXSM Stock - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXSM shares.
View AXSM analyst ratings
or view top-rated stocks.

What is Axsome Therapeutics' stock price forecast for 2023?

12 brokers have issued 1-year price targets for Axsome Therapeutics' shares. Their AXSM share price forecasts range from $75.00 to $210.00. On average, they expect the company's stock price to reach $108.15 in the next twelve months. This suggests a possible upside of 57.4% from the stock's current price.
View analysts price targets for AXSM
or view top-rated stocks among Wall Street analysts.

How have AXSM shares performed in 2023?

Axsome Therapeutics' stock was trading at $77.13 at the beginning of 2023. Since then, AXSM stock has decreased by 10.9% and is now trading at $68.70.
View the best growth stocks for 2023 here
.

Are investors shorting Axsome Therapeutics?

Axsome Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totaling 7,940,000 shares, an increase of 5.2% from the December 31st total of 7,550,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is presently 5.9 days. Approximately 22.4% of the company's shares are short sold.
View Axsome Therapeutics' Short Interest
.

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our AXSM earnings forecast
.

How can I listen to Axsome Therapeutics' earnings call?

Axsome Therapeutics will be holding an earnings conference call on Monday, February 27th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) posted its quarterly earnings data on Monday, November, 7th. The company reported ($1.03) EPS for the quarter, beating analysts' consensus estimates of ($1.10) by $0.07. The firm had revenue of $16.85 million for the quarter, compared to analysts' expectations of $16.59 million.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cannell & Co. (0.85%), Iridian Asset Management LLC CT (0.73%), Simplex Trading LLC (0.00%), Peregrine Capital Management LLC (0.22%), Hennion & Walsh Asset Management Inc. (0.21%) and Lindbrook Capital LLC (0.19%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends
.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $68.70.

How much money does Axsome Therapeutics make?

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $2.98 billion. The company earns $-130,400,000.00 in net income (profit) each year or ($4.06) on an earnings per share basis.

How many employees does Axsome Therapeutics have?

The company employs 108 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.

This page (NASDAQ:AXSM) was last updated on 2/5/2023 by MarketBeat.com Staff